Rectal Cancer Survival for Residual Carcinoma In Situ Versus Pathologic Complete Response After Neoadjuvant Therapy

By sjmartinez • June 14, 2024

Kohrman NM, Wlodarczyk JR, Ding L, McAndrew NP, Algaze SD, Cologne KG, Lee SW, Koller SE. Rectal Cancer Survival for Residual Carcinoma In Situ Versus Pathologic Complete Response After Neoadjuvant Therapy. Dis Colon Rectum. 2024 Jul 1;67(7):920-928. doi: 10.1097/DCR.0000000000003261. Epub 2024 Mar 18. PMID: 38498775.

Tags: Hematology/Oncology, Publications

Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD

Okamoto I, Cho BC, Goldberg SB, Goldman JW, de Langen AJ, Piotrowska Z, Riess JW, Yu HA, Garcia Campelo MR, Cetnar J, Kim YJ, Novello[...]

Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biology

Marks JA, Maniar R, Ramchandran KJ, Pietroluongo E, Altan M, Singhal S, Aldea M, Goldman JW, Reiss JW, Wakelee H, Loehrer PJ, Chiara Garassino M,[...]

Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer

Semenova G, Frank SB, Dumpit R, Han W, Coleman I, Gulati R, Dirican CD, Arman T, Maruwan J, Morrissey C, Haffner MC, Nelson PS, Lee[...]